← Back to Clinical Trials
Recruiting NCT07543601

NCT07543601 Enhanced COPD Management in Suspected Lung Cancer Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07543601
Status Recruiting
Phase
Sponsor Ditte Krag-Hansen
Condition COPD (Chronic Obstructive Pulmonary Disease)
Study Type INTERVENTIONAL
Enrollment 280 participants
Start Date 2026-03-06
Primary Completion 2027-06-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Tailored COPD consultations

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 280 participants in total. It began in 2026-03-06 with a primary completion date of 2027-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Identifying and treating COPD in patients undergoing lung cancer evaluation is crucial. Early intervention could lead to better management of both diseases, improving health status, reducing healthcare costs, and potentially increasing survival rates. This study aims to assess the impact of early diagnosis and optimal treatment of COPD on clinical outcomes in patients under evaluation for lung cancer. The study will combine information through an open-label RCT at the Lung Cancer Investigation Unit at Lillebaelt Hospital Vejle. The findings could inform clinical practice by emphasizing the importance of integrated care approaches for patients with coexisting COPD and lung cancer, ultimately leading to better health outcomes.

Eligibility Criteria

Inclusion Criteria: * Undergoing diagnostic evaluation for suspected lung cancer * Spirometry showing obstructive airflow limitation (FEV₁/FVC \< 75 % or FEV₁ \< 80 %, and no reversibility) at the first outpatient visit at the lung cancer evaluation Exclusion Criteria: * Presence of significant comorbidities that may interfere with diagnostic procedures or spirometry * Pregnant or breastfeeding women

Contact & Investigator

Central Contact

Ditte Krag-Hansen, MD, PhD student

✉ ditte.krag-hansen@rsyd.dk

📞 +45 7940 5720

Frequently Asked Questions

Who can join the NCT07543601 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying COPD (Chronic Obstructive Pulmonary Disease). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07543601 currently recruiting?

Yes, NCT07543601 is actively recruiting participants. Contact the research team at ditte.krag-hansen@rsyd.dk for enrollment information.

Where is the NCT07543601 trial being conducted?

This trial is being conducted at Vejle, Denmark.

Who is sponsoring the NCT07543601 clinical trial?

NCT07543601 is sponsored by Ditte Krag-Hansen. The trial plans to enroll 280 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology